Creating Value For Our Shareholders

Why Invest in Bayer

Report Highlights

Half-Year Financial Report 2022

Investment Case

Event Highlights

CH Webinar_Teaser

September 15, 2022

Consumer Health Investor Webinar September 2022

PH_Asundexian_Header

August 29, 2022

Asundexian Investor Webinar August 2022

Girl using a drone with the sunset in the background

August 11, 2022

Crop Science Field Technology Showcase

Hands_with_smartphone

Investor Conference Call

Q2 2022 Results

enhancing-transparency

Enhancing Transparency: Bayer’s UN Global Compact adherence Webinar

Investor Conference Call

Q1 2022 Results

Werner Baumann & Norbert Winkeljohann

Virtual Event: Annual Stockholders’ Meeting 2022

womans face with data sheets

Bayer Breakthrough Innovation Forum

VIEW ALL EVENTS

News from Bayer

September 08, 2022

Not intended for U.S. and UK Media

Aflibercept 8 mg first to achieve extended injection intervals of 16 weeks in up to 89% of patients

September 02, 2022

Not intended for U.S. and UK Media

Kerendia™ (finerenone) receives updated label in the U.S. to include findings from Phase III FIGARO-DKD cardiovascular outcomes study

September 01, 2022

Kimberly Mathisen appointed to the Supervisory Board of Bayer AG

Sustainability & Governance

Our Commitment to Sustainability

Discover More Investor Resources

Returning Value to Shareowners

Detailed Insight into Debt & Fixed Income

Business man pointing on rising graph

Discover Our Interactive Stock Charts

CORPORATE GOVERNANCE

Managing and Supervising an Enterprise

CONTACT IR TEAM

Get In Touch With Us

Subscribe To Our Latest Investor News

USES AND SAFETY RECORD

Let’s Talk About Glyphosate

Learn About The Litigation

Glyphosate Litigation Facts